Icosavax Initiates Phase 1/1b Trial of VLP Vaccine Candidate Against Respiratory Syncytial Virus
09 sept. 2021 08h00 HE | Icosavax, Inc.
SEATTLE, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Icosavax, Inc. (NASDAQ: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines...
2021 Education Next Survey Reveals Parental Support for School Covid-Safety Measures Despite Vaccination Hesitancy
31 août 2021 04h30 HE | Education Next
Cambridge, Massachusetts, Aug. 31, 2021 (GLOBE NEWSWIRE) -- While a large percentage of parents support Covid-safety measures for students, many are reluctant to vaccinate their children, the 15th...
Mountain Valley MD Holdings to Graduate to OTCQX Best Market, Updates Broader Up-Listing Strategy
26 août 2021 16h01 HE | Mountain Valley MD Holdings Inc.
TORONTO, Aug. 26, 2021 (GLOBE NEWSWIRE) -- Mountain Valley MD Holdings Inc. (the “Company” or “MVMD”) (CSE: MVMD) (FRA: 20MP) is pleased to announce that effective August 27, 2021, it will graduate...
Sorrento Reports Promising Results With mRNA Vaccine For COVID-19 Delivered With The MuVaxx Lymphatic Drug Delivery Device
26 août 2021 12h28 HE | Sorrento Therapeutics, Inc.
Sorrento’s mRNA vaccine (“STI-mRNA”) delivered with the MuVaxx™ Lymphatic Drug Delivery Device (“MuVaxx”), at 1/10th of the dose vs an LNP-mRNA reference standard1 (“LNP-mRNA”) delivered...
Pfizer and BioNTech Announce Collaboration with Brazil’s Eurofarma to Manufacture COVID-19 Vaccine Doses for Latin America
26 août 2021 06h46 HE | BioNTech SE
NEW YORK, USA and MAINZ, GERMANY, August 26, 2021 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the signing of a letter of intent with Eurofarma Laboratórios SA, a Brazilian...
Pfizer und BioNTech geben Zusammenarbeit mit brasilianischem Unternehmen Eurofarma zur Herstellung von COVID-19-Impfstoffdosen in Lateinamerika bekannt
26 août 2021 06h46 HE | BioNTech SE
NEW YORK, USA und MAINZ, DEUTSCHLAND, August 26, 2021 — Pfizer Inc. (NYSE: PFE, „Pfizer“) und BioNTech SE (Nasdaq: BNTX, „BioNTech“) gaben heute die Unterzeichnung einer Absichtserklärung mit dem...
Pfizer and BioNTech Initiate Rolling Submission of Supplemental Biologics License Application to U.S. FDA for Booster Dose of COMIRNATY® in Individuals 16 and Older
25 août 2021 12h10 HE | BioNTech SE
New Phase 3 data show booster (third) dose of COMIRNATY induces significant SARS-CoV-2 neutralizing antibody titers and demonstrated a favorable safety and tolerability profileSARS-CoV-2 neutralizing...
Pfizer und BioNTech leiten den Einreichungsprozess einer ergänzenden Biologics License Application bei der FDA für die Zulassung einer Auffrischungsimpfung mit COMIRNATY ® bei Personen ab 16 Jahren ein
25 août 2021 12h10 HE | BioNTech SE
Neue Daten der Phase-3-Studie zeigen, dass eine Auffrischungsimpfung (dritte Dosis) mit dem COVID-19-Impfstoff von Pfizer und BioNTech signifikante neutralisierende Antikörpertiter gegen SARS-CoV-2...
190705_Biontech_Logo_RGB_Dark Green (Preferred)_0.png
Pfizer-BioNTech COVID-19 Vaccine COMIRNATY® Receives Full U.S. FDA Approval for Individuals 16 Years and Older
23 août 2021 11h55 HE | BioNTech SE
COMIRNATY is the first COVID-19 vaccine to be granted FDA approval Approval is based on a comprehensive submission package including six-month efficacy and safety data after second doseMore than 1.2...
In Response to Delta, 63% of Small to Medium-Sized Enterprises Have Taken Steps Regarding Mandating COVID-19 Vaccine
23 août 2021 08h00 HE | JumpCloud
LOUISVILLE, Colo., Aug. 23, 2021 (GLOBE NEWSWIRE) -- JumpCloud today announced the findings from its recent survey, “2021 Impact of COVID-19 on SMEs.” With global changes in the workplace due to...